- Home
- AME vs MRNA Comparison
AME vs MRNA Comparison
Compare AME & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AME | MRNA |
|---|---|---|
| Founded | 1930 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2B | 61.6B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AME | MRNA |
|---|---|---|
| Price | $252.03 | $188.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 12 |
| Target Price | ★ $233.27 | $34.27 |
| AVG Volume (30 Days) | 1.2M | ★ 12.9M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | 7.93 | ★ 21.77 |
| EPS | ★ 3.51 | N/A |
| Revenue | $7,401,116,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $8.86 | $9.36 |
| Revenue Next Year | $5.57 | $15.43 |
| P/E Ratio | $71.27 | ★ N/A |
| Revenue Growth | ★ 6.63 | 4.29 |
| 52 Week Low | $179.30 | $22.28 |
| 52 Week High | $261.16 | $208.90 |
Technical Indicators
Market Signals| Indicator | AME | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 75.87 |
| Support Level | $225.41 | $43.35 |
| Resistance Level | $261.16 | N/A |
| Average True Range (ATR) | 4.77 | 11.47 |
| MACD | 1.97 | 2.59 |
| Stochastic Oscillator | 83.93 | 86.71 |
Price Performance
Historical ComparisonAbout AME AMETEK Inc.
Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns more than 40 autonomous industrial businesses operating across research, aerospace, energy, medical, and manufacturing. Ametek segments its business into two operating groups: the electronic instruments group and the electromechanical group. The EIG sells a broad portfolio of analytical, test, and measurement instruments, while the EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets it operates in.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.